Fractional Laser-assisted Hair Regrowth and Microneedling for the Treatment of Alopecia Areata: A Review

Robert J. Dabek, Daniel S. Roh, Derman Ozdemir, William G. Austen Jr., Branko Bojovic

1. Plastic Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, USA 2. Internal Medicine, Saba University School of Medicine, The Bottom, Caribbean Netherlands, NLD

Corresponding author: Robert J. Dabek, robert.j.dabek@gmail.com

Abstract

Alopecia areata (AA) affects approximately 2.1% of the population, with women being affected more often than men. Current therapies consisting of topical corticosteroids or intralesional injections are often the first choices for treatment, but are limited by unsatisfactory outcomes or risks to patients. Recently, fractional lasers and microneedling, with or without the addition of topical agents, have been examined as treatment options. A literature review was performed to evaluate the efficacy of fractional lasers in the treatment of AA. A total of six fractional lasers and two microneedling studies consisting of small prospective and retrospective studies, and case reports were reviewed. The number of trials and participants are limited, but evidence suggests that fractional lasers and microneedling may be effective therapeutic approaches when coupled with topical agents. Larger studies are required to better understand the effects of these treatment modalities for AA.

Introduction And Background

Alopecia areata (AA), an autoimmune condition, characterized by a chronic remitting-relapsing course of patchy hair loss, affects approximately 2.1% of the population [1]. Adults and children are affected, with women being at slightly higher risk [1]. It is estimated that approximately 34%-50% of patients with mild disease of less than one-year duration will have spontaneous resolution without the need for treatment, and approximately 14%-25% will have eventual total loss of hair on the scalp [2]. Almost a quarter of patients with AA have a family history of disease, suggesting a genetic predisposition [2]. Although AA is considered benign, psychological distress may result, disrupting patients’ self-esteem, and overall quality of life [3].

The exact pathologic process causing AA is unknown. It is hypothesized that there may be a loss of hair follicle (HF) immune privilege triggering the involvement of innate and adaptive components of the immune system. These interactions occur through oxidative stress ligands such as major histocompatibility complex (MHC) class I polypeptide-related sequence A (MICA), UL16-binding proteins (ULBP), and activated natural killer group 2D (NKG2D) receptors [4]. Patients will present clinically with ovoid patches of hair loss which may be present on the scalp, or elsewhere on the body. Patients who seek treatment will usually have scalp involvement. When the alopecia causes involvement of the entire scalp it is termed alopecia totalis, and when the entire body is involved, alopecia universalis. There may be nail changes such as pitting, ridging, and thickening [5]. About 70%-90% of hairs shift out of anagen phase, into catagen or telogen phases [6]. The terminal hairs are first to be involved, with the vellus hairs being involved as the disease progresses. Histopathologic changes are dependent on the duration of the disease and may be classified as early active (acute and subacute), or longstanding (chronic). During the early active stage, a peribulbar lymphocytic infiltrate will be visible, affecting the terminal HFs [5]. In longstanding or chronic stages, the lymphocytic infiltrate will involve the vellus hair as well, and most of the HFs will be in the catagen or telogen phase, with some being in the anagen phase (miniaturized and rapidly cycling hairs with mixed features of the other three phases) [5-7].

A number of treatment options are available for hair regrowth in AA but none have been shown to be universally effective, or to completely rid the patient of disease. Few treatments have been verified by randomized controlled trials (RCTs), and the relatively high rate of spontaneous remission often clouds the interpretation of results. Topical steroids may be the first choice of treatment for mild disease limited to small areas. Results of RCTs vary, but some individuals appear to respond favorably [8-10]. Despite varying efficacy and the risk of developing folliculitis, topical steroids remain a first line choice due to their relative safety. Intralesional corticosteroid injections are effective, but are limited to use in small lesions or in cosmetically sensitive areas [11]. Skin atrophy is a common side effect in areas treated repeatedly, or with high doses [11]. Oral corticosteroids have also been used to treat AA and will produce regrowth in some patients [11]. However, prolonged treatment is needed to maintain the results, and does not justify the risk. Minoxidil, the treatment of choice for androgenic alopecia, has also been tested for the use in AA. One
randomized controlled trial using topical minoxidil for the treatment of AA has demonstrated improved induction of hair growth over placebo in patients with mild disease [12], however further trials failed to show any improvement [13-15]. Nonetheless, this may be an option for patients due to the safety of the treatment. Perhaps the most underutilized option, contact immunotherapy, was first described in the 1970s and remains one of the most effective treatments for AA [16]. Typically, a contact allergen is applied weekly until hair regrowth is identified, at which point frequency may be reduced as needed. The process is intensive, requiring weekly visits for 6–32 months, and there is a risk for adverse effects including lymphadenopathy, severe dermatitis, and uncommonly severe urticaria and vitiligo [17-18]. There have also been concerns that several of the agents used are mutagenic [19-20]. Other treatment options including immunomodulators, low-level laser/light, photochemotherapy (psoralen plus ultraviolet A) [11], sulfasalazine, and others have been tested and showed mixed results [11]. Given the shortcomings of current treatments, new treatment modalities are currently being researched with a goal to improve results while minimizing adverse effects.

Review

Methods

A literature search was performed in June of 2018 to identify publications involving fractional laser and microneedling used for the treatment of AA. PubMed was searched with the following terms: fractional laser OR microneedling OR microneedle OR micro needling AND alopecia. Abstracts of the 40 results, and pertinent references, were reviewed for inclusion. All trials, published in English, utilizing fractional lasers or microneedling for the treatment of AA were included.

Results

A total of six laser and two microneedling studies consisting of small prospective and retrospective studies, and case reports, were reviewed (Table 1). Fifty-seven patients, both males (n=29) and females (n=28), with AA were included.
| Author, year | Resurfacing technique | Additional treatment(s) | Study Design | Laser/needling settings | Number of sessions | Interval | Number of Subjects | Alopecia type | Adverse effects | results |
|-------------|-----------------------|-------------------------|-------------|-------------------------|--------------------|---------|--------------------|--------------|----------------|---------|
| Yalici-Armagan et al., 2016 [21] | CO₂ laser (10600 nm) Nd:YAG* laser (1064 nm) | None | Prospective, split lesion study | 10-45 mJ/cm², 75-100 spots/cm² 10 J/cm², 30 millisecond pulse | 3-6 | 2-4 weeks 2-8 weeks | 32 (19 male, 13 female) | Alopecia areata | Pain | No improvement |
| Issa et al., 2016 [22] | CO₂ laser (10600 nm) | Topical corticosteroid | Prospective study | 60 mJ/spot, 100 spots/cm² 2 passes | 1-6 | 3 weeks | 5 (1 male, 4 female) | Alopecia areata | Mild burning pain | Improvement in all patients |
| Eckert et al., 2016 [23] | Erbium glass laser (1550 nm) | None | Retrospective series | Variable | 2-3 | 3-6 weeks | 5 (2 male, 3 female) | Alopecia areata | Pain | Improvement in all treated lesions |
| Cho et al., 2013 [24] | CO₂ laser (10600 nm) Erbium glass laser (1550 nm) | Variable | Retrospective series | 30-50 mJ/spot, 150 spots/cm² 6-8 mJ/spot, 300 spots/cm² 2 passes | 2-3 | 3-6 weeks | 3 (1 male, 2 female) | Ophiasis | Pain, burning, scaling, erythema, and edema | 2 of 3 patients demonstrated improvement |
| Tsai, 2011 [25] | Erbium glass laser (1550 nm) Intralesional corticosteroid injection | Split scalp case report | Not reported | 12 | 1 week | 1 male | Alopecia areata | None | Improvement vs steroid alone |
| Yoo et al., 2010 [26] | Erbium glass laser (1550 nm) | None | Case report | 10-15 mJ/spot, 300 spots/cm², 2 passes | 24 | 1 week | 1 male | Alopecia areata | None | Complete regrowth in treated lesions |
| Mysore et al., 2014 [27] | Microneedle dermaroller | Topical corticosteroids | Case series | 3 | 3 weeks | 2 males | Alopecia areata | None | Improvement |
| Yoo et al., 2010 [28] | 1 mm microneedle roller | Topical methyl 5-aminolevulinate acid and photodynamic therapy with red light | Split lesion case series | 3 | 4 weeks | 8 (2 male, 6 female) | Alopecia areata | Mild pain, and erythema | No improvement |

**TABLE 1: Summary of skin resurfacing studies for the treatment of alopecia areata**

*Nd:YAG: neodymium-doped yttrium aluminum garnet.

Fractional non-ablative Erbium glass [23-26], fractional ablative CO₂ [21-22,24], and non-ablative neodymium-doped yttrium aluminum garnet (Nd:YAG) lasers [21] have been used for treatment of AA. Both the CO₂ and Erbium glass lasers have a chromophore of water and effectively vaporize or coagulate tissue upon which they act [29]. The non-ablative Nd:YAG laser has a target chromophore of melanin and can penetrate effectively into deeper tissue [30].

A prospective split-lesion trial examining the effect of the CO₂ laser and Nd:YAG laser, without topical drug application, on 19 men and 13 women with AA failed to show an increase in mean hair density [21]. The study subjects had three affected areas allocated to treatment with either Nd:YAG or CO₂ laser, or no treatment. In a prospective series, investigators paired a single administration of topical corticosteroid with CO₂ laser treatment [22]. All five patients exhibited clinical improvement, sustained at 12-month follow-up. One patient had additional control patches treated with laser alone which were noted to have no improvement. In a retrospective review of three patients with AA (ophiasis), treated with a combination of
CO₂ and Erbium glass lasers, two saw moderate to marked improvement, while one did not show any change [24]. Of the patients with improvement, one was treated with concurrent intrafollicular corticosteroid injections.

Two case reports and one additional case series using the Erbium glass laser have been identified and included for review in our study [23-25,26]. A case of complete regrowth of areas of alopecia areata occurred in a male patient after 24 treatment sessions, at weekly intervals [26]. No other treatments were given during this time and the patient maintained complete hair regrowth at six-month follow-up. Another case of a 28-year-old man with alopecia totalis treated with Erbium glass laser in conjunction with intralesional corticosteroid has been reported [23]. After 12 weekly treatment sessions, it was noted that the site treated with combination therapy was greatly improved over corticosteroid injection alone. In a case series of five patients with AA treated with Erbium glass laser, patients had full, or near full regrowth at three-months with no recurrence of any of the treated patches at two-to four-year follow-up [23].

Only two identified reports evaluated the efficacy of microneedling devices in the treatment of AA. In a series of eight patients, microneedling in conjunction with methyl 5-aminolevulinate and photodynamic therapy was ineffective for the treatment of AA [28]. Conversely, in a case series of two men with AA, a combination of microneedling and topical corticosteroids was found to be effective at restoring hair growth [27].

Discussion

In the reviewed studies, the treatments were tolerated by patients and the adverse effects were limited to pain, and transient erythema, edema, and pruritus. There is very little evidence to suggest that microneedling or treatment with fractional laser devices alone aids in the restoration of hair growth in patients with AA. The largest study to date examined the effects of fractional ablative CO₂ laser and non-ablative Nd:YAG laser in a prospective split-lesion study of 32 patients [21]. There was no notable difference found between treatment and non-treatment sites. One report showed mixed results [24], while another showed positive effects [26]. These mixed results can be attributed to the natural remitting-relapsing course of the disease. However, one case series of five patients noted improvement with no recurrence of those lesions after two to four years [23]. These results would be difficult to explain solely by disease course. As the laser type and settings remain heterogeneous throughout these studies, it is possible that the laser settings used for these five patients can produce favorable results. Given the poor evidence for the use of these techniques alone, the utility of the fractional laser and microneedling devices for the treatment of AA is probably centered around the ability of these treatments to enhance drug delivery to the target tissue. All studies using topical corticosteroids in conjunction with laser or microneedling treatments showed improvement in hair growth. However, other than a single case report [27], there have been no comparative studies to suggest that combined therapy is more effective than topical steroids alone. There are significant limitations to this review. Many of the examined studies are case reports or small series. Given the heterogeneity of patients and treatment types, it is difficult to draw a substantial conclusion. Many treatment variables remain untested and unknown. Laser type, settings, treatment frequency, and topical therapeutic options require further examination.

One of the proposed mechanisms by which microneedling and fractional lasers may induce hair regrowth is by altering the microenvironment and causing changes to the local immune cells [51]. Through the release of various chemokines, there is potential to displace the perifollicular infiltrate to other areas of the dermis and epidermis. It has also been proposed that laser light can trigger apoptosis of lymphocytic cells, relieving the immune-mediated destruction of the follicles [24,26]. Alternatively, the paradoxical hair growth seen in cases of laser hair removal [32-33] may be a mechanism by which hair restoration could occur in patients with AA. It is hypothesized that the stimulation, and incomplete destruction of the HF can stimulate a regenerative response triggering the HF to enter anagen. Similarly to the proposed mechanism of minoxidil, enhanced blood flow to the HF caused by microtrauma could enhance hair growth. Additionally, these modalities have both been shown to enhance dermal drug delivery through the creation of columns of tissue injury, acting as a conduit for the passage of topically applied substances [34-35].

Conclusions

Microneedling and fractional laser therapy have been shown to have minimal risk of severe or lasting adverse effects within a small group of patients with AA. Several mechanisms may be responsible for the induction of hair growth after skin resurfacing procedures, though the precise mechanisms responsible remain to be determined. The paucity of clinical data for these new treatment modalities does not allow one to make any definitive conclusions regarding their efficacy. There is potential for the therapies to be effective when combined with topical drug administration due to enhanced drug delivery. Further examination in the form of randomized or split-lesion studies is needed to determine whether this approach is clinically viable.
Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Mirozov S, Schrum AG, Davis MDP, Torgerson RR: Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990-2009. J Invest Dermatol. 2014, 134:1141-2. 10.1038/jid.2013.464
2. Hall SPM, Wood ML, Hutchinson PE, Sladden M, Messenger AG: Guidelines for the management of alopecia areata. Br J Dermatol. 2003, 149:692-699. 10.1046/j.1365-2133.2003.05535.x
3. Davis DS, Callender VD: Review of quality of life studies in women with alopecia. Int J Womens Dermatol. 2018, 4:18-22. 10.1016/j.jiwdd.2017.11.007
4. Rajabi F, Drake LA, Senna MM, Rezaei N: Alopecia areata: a review of disease pathogenesis. Br J Dermatol. 2018, 179:1035-48. 10.1111/bjd.16808
5. Stefanato CM: Histopathology of alopecia: a clinicopathological approach to diagnosis. Histopathology. 2010, 56:24-38. 10.1111/j.1365-2559.2009.03449.x
6. Eudy G, Solomon AR: The histopathology of noncicatricial alopecia. Semin Cutan Med Surg. 2006, 25:35-40. 10.1016/j.sxder.2006.01.005
7. Whiting DA: Histopathologic features of alopecia areata: a new look. Arch Dermatol. 2005, 139:1555-9. 10.1001/archderm.139.12.1555
8. Tosti A, Piraccini BM, Pazzaglia M, Vincenzi C: Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol. 2003, 49:96-98. 10.1067/mjd.2003.425
9. Tosti A, Iorizzo M, Botta GL, Milani M: Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial. J Eur Acad Dermatol Venereol. 2006, 20:1243-7. 10.1111/j.1468-3083.2006.01781.x
10. Charuwitchitratana S, Wattanakrai P, Tantrattanakorn S: Randomized double-blind placebo-controlled trial in the treatment of alopecia areata with 0.25% desoximetasone cream. Arch Dermatol. 2000, 136:1276-7.
11. Messenger AG, McKillop J, Farrant P, McDonagh AJ, Sladden M: British Association of Dermatologists’ guidelines for the management of alopecia. Br J Dermatol. 2012, 166:916-26. 10.1111/j.1365-2133.2012.10955.x
12. Fenton DA, Wilkinson JD: Topical minoxidil in the treatment of alopecia areata. Br Med J. 1985, 287:1015-17. 10.1136/bmj.287.6398.1015
13. Ranchoff RE, Bergfeld WF, Stuck WD, Subichin SJ: Extensive alopecia areata: results of treatment with 3% topical minoxidil. Cleve Clin J Med. 1989, 56:149-54.
14. Price VH: Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. J Am Acad Dermatol. 1987, 16:730-6. 10.1016/S0190-9622(87)70095-4
15. Vestney JP, Savin JA: A trial of 1% minoxidil used topically for severe alopecia areata. Acta Derm Venereol. 1986, 66:179-80.
16. Daman LA, Rosenberg EW, Drake L: Treatment of alopecia areata with dinitrochlorobenzene. Arch Dermatol. 1978, 114:1036-8. 10.1001/archderm.1978.01640190024007
17. Henderson CA, Ichihyanu A: Vitiligo complicating diphenycyprone sensitization therapy for alopecia universalis. Br J Dermatol. 1995, 133:496-7. 10.1111/j.1365-2133.1995.tb02692.x
18. Alam M, Gross EA, Savin RC: Severe urticarial reaction to diphenycyproponene therapy for alopecia areata. J Am Acad Dermatol. 1999, 40:110-2. 10.1016/S0190-9622(99)70540-2
19. Wilkerson MG,Connor TH, Henkin I, Wilkin JK, Matney TS: Assessment of diphenycyproponene for photochemically induced mutagenicity in the Ames assay. J Am Acad Dermatol. 1987, 17:606-11. 10.1016/S0190-9622(87)70244-8
20. Summer KH, Goggelmann W: 1-chloro-2,4-dinitrobenzene depletes glutathione in rat skin and is mutagenic in Salmonella typhimurium. Mutat Res. 1980, 77:91-5. 10.1016/0165-1218(80)90124-X
21. Yalici-Armagan B, Elcin G: The effect of neodymium: yttrium aluminium garnet and fractional carbon dioxide lasers on alopecia areata: a prospective controlled clinical trial. Dermatol Surg. 2016, 42:500-6. 10.1177/10775282166400649
22. Issa MCA, Pires M, Silveira P, Xavier De Brito E, Sasajima C: Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata: a randomized, double-blind placebo-controlled trial. J Am Acad Dermatol. 2017, 76:124-9. 10.1016/j.jaad.2016.02.521
23. Eckert MM, Gundin NL, Crespo RL: Alopecia areata: good response to treatment with fractional laser in 5 cases. J Cosmo Trichol. 2016, 2:16-9. 10.4103/0974-2077.129989
24. Cho S, Choi MJ, Zheng Z, Goo B, Kim DY, Cho SB: Clinical effects of non-ablative and ablative fractional lasers on various hair disorders: a case series of 17 patients. J Cosmet Laser Ther. 2015, 17:54-9. 10.3109/14764172.2015.967778
25. Tsai Y-C: Alopecia areata treated with fractional photothermolysis laser: a case report. J Am Acad Dermatol. 2016, 74:132. 10.1016/j.jaad.2016.02.521
26. Yoo KH, Kim MN, Kim BJ, Kim CW: Treatment of alopecia areata with fractional photothermolysis laser. Int J Dermatol. 2010, 49:845-7. 10.1111/j.1365-4632.2009.04250.x
27. Mysore V, Chandrashekar B, Yepuri V: Alopecia areata--successful outcome with microneedling and triamcinolone acetonide. J Cutan Aesthet Surg. 2014, 7:65. 10.4103/0974-2077.129989
28. Yoo KH, Lee W, Li K, Kim BJ, Kim MN: Photodynamic therapy with methyl 5-aminolevulinate acid might be ineffective in recalcitrant alopecia totalis regardless of using a microneedle roller to increase skin penetration. Dermatol Surg. 2010, 36:618-22. 10.1111/j.1524-7247.2010.01515.x
29. Issler-Fisher AC, Waibel JS, Donelan MB: Laser modulation of hypertrophic scars: technique and practice. Clin Plast Surg. 2017, 44:757-66. 10.1016/j.cps.2017.05.007

2019 Dabek et al. Cureus 11(6): e4943. DOI 10.7759/cureus.4943
30. Savas JA, Ledon JA, Franca K, Nouri K: Overview of lasers used in dermatology. Handbook of Lasers in Dermatology, Nouri K (ed): Springer, London; 2014. 29-35. 10.1007/978-1-4471-5322-1_3

31. Manstein D, Herron GS, Sink RK, Tanner H, Anderson RR: Fractional photothermolysis: a new concept for cutaneous remodeling using microscopic patterns of thermal injury. Lasers Surg Med. 2004, 34:426-58. 10.1002/lsm.20048

32. Kontoes P, Vlachos S, Konstantinos M, Anastasia L, Myrto S: Hair induction after laser-assisted hair removal and its treatment. J Am Acad Dermatol. 2006, 54:64-7. 10.1016/j.jaad.2005.09.034

33. Bouzari N, Firooz AR: Lasers may induce terminal hair growth. Dermatol Surg. 2006, 32:460. 10.1111/j.1524-4725.2006.32092.x

34. Waibel JS, Rudnick A, Shaglov DR, Nicolazzo DM: Update of ablative fractionated lasers to enhance cutaneous topical drug delivery. Adv Ther. 2017, 34:1840-9. 10.1007/s12325-017-0516-9

35. Braun SA, Gerber PA, Hevezi PA: Needling-assisted drug delivery: enhanced response to ingenol mebutate after microneedling. Dermatol Surg. 2017, 43:978-9. 10.1097/DSS.0000000000001026